Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in relation to glycaemic control and use of oral antidiabetic drugs (OADs). Methods: Study of Once Daily Levemir was a 24‐week international observational study involving 10 countries which evaluated the safety and effectiveness of initiating once‐daily insulin detemir in people with type 2 diabetes mellitus (T2DM) being treated with one or more OADs (clinical trial number NCT00825643 and NCT00740519). Results: A total of 17 374 participants were enrolled in the study: aged 62 ± 12 years, 53% male, T2DM duration 10 ± 7 years, body mass index 29.3 ± 5.4 kg/m 2 . Pre‐insulin HbA1c was 8.9 ± 1.6%. The proportion of patients with HbA1c ≥9.0% ranged from 64% (UK) to 23% (Poland). Pre‐insulin OAD treatment included metformin (81%), sulphonylureas (59%), glinides (16%), thiazolidinediones (TZD) (12%), α ‐glucosidase inhibitors (12%) and dipeptidyl peptidase (DPP)‐IV inhibitors (7%). The mean starting dose of insulin detemir for the total cohort was 0.16 ± 0.09 U/kg. Differences in OAD use and insulin doses at initiation were evident among participating countries. The largest proportional changes in OAD prescribing at insulin initiation were seen with glinides (+15%), sulphonylureas (−19%), TZD (−31%) and DPP‐IV inhibitors (−28%). Conclusions: Despite well‐documented benefits of timely glycaemic control and consensus guidelines encouraging earlier use of insulin, considerable clinical inertia exists with respect to initiating appropriate insulin therapy in people with T2DM. Considerable regional differences exist in the timing of insulin initiation and in the use of OADs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The results of an analysis of the 10-year follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) suggest that patients receiving initial intensive treatment do have reductions in cardiovascular- and all-cause mortality [18].”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“premixed and basal-bolus regimens) [37].”
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 2×
“Typically, HbA1c levels are higher in patients commencing insulin therapy relative to patients receiving OAD treatment intensification [3,23,24].”
Clinical Inertia Contributes to Poor Diabetes Control in a Primary Care Setting
Ziemer, D. C., Miller, C. D., Rhee, M. K., Doyle, J. P., Watkins, C., Cook, C. B., Gallina, D. L., El-Kebbi, I. M., Barnes, C. S., Dunbar, V. G., et al. (2005) · The Diabetes Educator · doi:10.1177/0145721705279050 · Cited by 208 · cited 13×
“SOLVE is currently the largest study of basal insulin initiation in patients with T2DM, and the results confirm clinical inertia in treatment intensification shown in registry studies involving similar sized patient cohorts.”
BackgroundInfluential
Cited by
Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise
Chen, Q., & Liu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201600038 · Cited by 290
Khunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12626 · Cited by 256
Self-citationIdentification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
“addition, the proportion of people with HbA1c >9% at time of insulin initiation varied from 23% (Poland) to 64% (UK and Turkey), suggesting the level of inertia varies between countries.(48)”
BackgroundSelf-citationAndreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Furler, J., O’Neal, D., Speight, J., Manski-Nankervis, J.-A., Gorelik, A., Holmes-Truscott, E., Ginnivan, L., Young, D., Best, J., dean, et al. (2017) · BMJ · doi:10.1136/bmj.j783 · Cited by 78
Metadata
- Authors
- Khunti, K., Damci, T., Meneghini, L., Pan, C. Y., Yale, J. ‐., & on behalf of the SOLVE Study Group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-04-22
- Volume
- 14
- Issue
- 7
- Pages
- 654-661
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2065380980
- Cited by
- 114
- References
- 5
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.